CARLSBAD, Calif. / Oct 30, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets. Lineage... Read More

Initial Program Focus Will Be On Addressing Manufacturing Scale CARLSBAD, Calif. / Sep 08, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the... Read More

H.C. Wainwright 27 th Annual Global Investment Conference Presentation on September 8, 2025 Baird's 2025 Global Healthcare Conference Presentation on September 9, 2025 CARLSBAD, Calif. / Sep 02, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic... Read More

Three-year term intended to advance preclinical development of ReSonance Up to $12 million of development costs to be contributed by William Demant Invest CARLSBAD, Calif. / Aug 26, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious neurological and ophthalmic conditions,... Read More

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes First Chronic Patient Treated in New Clinical Study of OPC1 in Patients with Subacute and Chronic Spinal Cord Injury Hosted the 3 rd Annual SCI Investor Symposium CARLSBAD, Calif. / Aug 12, 2025 /... Read More

CARLSBAD, Calif. / Aug 05, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its second quarter 2025 financial and operating results on Tuesday, August 12, 2025, following the close of the U.S. financial markets. Lineage management will also... Read More

Successful First-In-Human Use of New Parenchymal Spinal Delivery System First-ever Administration of OPC1 to a Chronic Injury Patient CARLSBAD, Calif. / Aug 04, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, announced today that the... Read More

Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site Evidence of retinal structural improvement persisted out to 3 years Anatomical and functional improvements occur following a single administration of OpRegen cell therapy CARLSBAD, Calif. / Jun 23, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a... Read More

Fully Virtual Event Scheduled for June 27, 2025 CARLSBAD, Calif. / Jun 05, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3 rd Annual Spinal Cord Injury Investor Symposium ("3 rd SCIIS").... Read More

CARLSBAD, Calif. / May 14, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the 3 rd Annual H.C. Wainwright BioConnect Investor Conference , in a fireside chat hosted by Joseph Pantginis, Ph.D.,... Read More

RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results to be featured June 21 st at Clinical Trials at the Summit 2025 Initiated Clinical Study of OPC1 Delivery Device for Patients with Subacute and Chronic Spinal Cord Injury Announced 3 rd Annual SCI Investor Symposium with Christopher & Dana Reeve Foundation CARLSBAD, Calif. / May 13, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE:... Read More

CARLSBAD, Calif. / May 12, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA)... Read More

CARLSBAD, Calif. / May 01, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host... Read More

Fully Virtual Event Scheduled for June 27, 2025 CARLSBAD, Calif. / Apr 22, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals... Read More

Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 CARLSBAD, Calif. / Apr 21, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, has been invited to join... Read More

Positive 24 Month Visual Acuity Data with OpRegen ® in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Signed Services Agreement with Genentech to Further Support Ongoing OpRegen Development OpRegen Received RMAT Designation from FDA Completed Two Financings Totaling $44 Million in Gross Proceeds; Potential for an Additional $36 Million in Gross Proceeds Upon Full Cash Exercise of... Read More

CARLSBAD, Calif. / Mar 05, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage... Read More

Safety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients CARLSBAD, Calif. / Feb 11, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED ( D elivery of O ligodendrocyte Progenitor Cells (OPCs)... Read More

CARLSBAD, Calif. / Feb 04, 2025 / Business Wire / Lineage Cell Therapeutics, Inc . (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Oppenheimer 35 th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The... Read More

Lineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross Proceeds Upon the Full Exercise of OpRegen ® Clinical Milestone-linked Warrants CARLSBAD, Calif. / Jan 27, 2025 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing... Read More

$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants CARLSBAD, Calif. / Nov 21, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously... Read More

$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants CARLSBAD, Calif. / Nov 20, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive... Read More

OpRegen ® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000 ® Index CARLSBAD, Calif. / Nov 14, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs,... Read More

CARLSBAD, Calif. / Nov 07, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a... Read More

CARLSBAD, Calif. / Oct 14, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Maxim Group 2024 Virtual Healthcare Summit , in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing... Read More

CARLSBAD, Calif. / Sep 25, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium , PSC-Derived Cell... Read More

ReSonance is Manufactured by a Proprietary Process, Developed In-House, at Clinical Scale, with Relevant In-Vitro Functional Activity Immediate-Use, Thaw-and-Inject Formulation Durably Engrafted in Multiple Preclinical Hearing Loss Models ReSonance is Currently Being Evaluated in a Functional Model of Hearing Loss CARLSBAD, Calif. / Sep 18, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE:... Read More

CARLSBAD, Calif. / Aug 13, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 4 th Annual Ophthalmology Virtual Conference being held on Thursday, August 15, 2024. Lineage’s... Read More

24 Month Visual Acuity Benefits from a Single Administration with OpRegen ® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program OPC1 Clinical Study Start Up Preparations Ongoing Hosted... Read More

CARLSBAD, Calif. / Aug 01, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 8, 2024, following the close of the U.S. financial markets. Lineage management will also host a... Read More

CARLSBAD, Calif. / Jul 02, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after the U.S. market opens on July 1, 2024, as part of the 2024 Russell indexes reconstitution. The... Read More

CARLSBAD, Calif. / May 30, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting... Read More

Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical CARLSBAD, Calif. / May 21, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today... Read More

Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting OPC1 Clinical Study Start Up Preparation Underway Received CIRM Grant to... Read More

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layers observed by optical coherence tomography (OCT) in patients with extensive bleb coverage of the GA lesion Data suggests OpRegen may counteract... Read More

CARLSBAD, Calif. / May 02, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Award Will Support 2 nd Annual Spinal Cord Injury Investor Symposium To Be Held June 26 and 27, 2024 CARLSBAD, Calif. / Apr 30, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for... Read More

CARLSBAD, Calif. / Apr 29, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the... Read More

CARLSBAD, Calif. / Apr 01, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture... Read More

Event Scheduled for June 26 and 27, 2024 CARLSBAD, Calif. / Mar 18, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by... Read More

CARLSBAD, Calif. / Mar 13, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to... Read More

CARLSBAD, Calif. / Mar 11, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 ( OpRegen ) will be presented at the 2024 Association for Research in Vision and... Read More

Advanced OpRegen ® For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech Closed $14 Million Registered Direct Offering OPC1 Investigational New Drug Amendment Cleared; New Clinical Trial Planned Initiated Development of Hypoimmune iPSC Cell Line for Neurology Indications Under Gene Editing Collaboration with Eterna Therapeutics Added to Russell 3000 ® Index Established 1 st Annual Spinal Cord Injury... Read More

CARLSBAD, Calif. / Feb 29, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets. Lineage management will also... Read More

The DOSED Clinical Study Will Evaluate a Novel Delivery Device in Subacute and Chronic Spinal Cord Injury Patients CARLSBAD, Calif. / Feb 13, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its... Read More

CARLSBAD, Calif. / Feb 09, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the company’s common shares at an offering price of $1.04 per common share. The price... Read More

CARLSBAD, Calif. / Feb 06, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the company’s common shares in a registered direct offering at an offering price of... Read More

CARLSBAD, Calif. / Jan 16, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) in geographic atrophy (GA) secondary to... Read More

CARLSBAD, Calif. / Dec 18, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1 , its investigational allogeneic oligodendrocyte progenitor cell... Read More

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of the Roche Group Additional RG6501 (OpRegen ® ) Data Presented at 23 rd Annual EURETINA Congress and 2023 Eyecelerator Meetings U.S. Patent Issued Covering Manufacturing and Differentiation Process for Retinal Pigment... Read More

CARLSBAD, Calif. / Nov 01, 2023 / Business Wire / Lineage Cell Therapeutics, Inc . (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Company Also Will Present at “Mapping the Future of Geographic Atrophy” Session at Eyecelerator@AAO 2023 CARLSBAD, Calif. / Oct 24, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, has been invited to present as part... Read More

CARLSBAD, Calif. / Oct 11, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”. The patent, which has been... Read More

CARLSBAD, Calif. / Oct 05, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov... Read More

CARLSBAD, Calif. / Sep 19, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Cantor Fitzgerald 2023 Global Healthcare Conference , in a fireside chat hosted by Kristen Kluska, Managing Director,... Read More

CARLSBAD, Calif. / Sep 13, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier:... Read More

CARLSBAD, Calif. / Sep 11, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Gary S. Hogge, D.V.M., M.S., Ph.D., Lineage’s Senior Vice President, Clinical & Medical Affairs, will present at the 2023 International Spinal Research Trust (ISRT) Network Meeting , being... Read More

CARLSBAD, Calif. / Sep 06, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company’s exclusive option... Read More

CARLSBAD, Calif. / Aug 29, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at Baird’s 2023 Global Healthcare Conference, in a fireside chat hosted by Jack K. Allen, CFA, Senior Research Analyst, Robert... Read More

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group FDA Type B Meeting Response Provides Path for New OPC1 Delivery Device Positive Topline Data Reported from Phase 1 VAC2 Study for the Treatment of NSCLC Lineage Added to Russell 3000 ® Index Established and Presented 1 st Annual Spinal Cord Injury Investor... Read More

CARLSBAD, Calif. / Aug 03, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 10, 2023, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Patients enrolled were diagnosed with refractory, metastatic or locally advanced, non-small cell lung cancer (NSCLC), for whom there were no other suitable treatment options Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated immune-related progressive disease No patients had treatment emergent serious adverse events and all patients completed per... Read More

CARLSBAD, Calif. / May 22, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000 ® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June... Read More

Additional RG6501 (OpRegen ® ) Phase 1/2a Clinical Study Results Presented at ARVO 2023 Enrolling Phase 2a Clinical Study of RG6501 (OpRegen) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group Awarded CIRM Grant to Support 1 st Annual Spinal Cord Injury Investor Symposium Signed Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune iPSC Lines Initiated... Read More

Award Will Support 1 st Annual Spinal Cord Injury Investor Symposium To Be Held June 29, 2023 CARLSBAD, Calif. / May 09, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received a grant from the California Institute for Regenerative Medicine (CIRM) ,... Read More

CARLSBAD, Calif. / May 04, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Preliminary Evidence of Durable Anatomical and Functional Improvements Following Administration of OpRegen Cells Extensive OpRegen Surgical Bleb Coverage of Areas of GA May Be Critical for Optimizing Patient Outcomes OCT Imaging With Segmentation Analysis is Advantageous in Assessment of Retinal Integrity Post-Treatment CARLSBAD, Calif. / Apr 26, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE:... Read More

CARLSBAD, Calif. / Apr 18, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference , on April 25 th , 2023... Read More

Inaugural Event on June 29, 2023, at the Sanford Consortium for Regenerative Medicine CARLSBAD, Calif. / Mar 30, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organization dedicated to advancing innovative research and... Read More

CARLSBAD, Calif. / Mar 20, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit , organized by the Foundation Fighting Blindness... Read More

CARLSBAD, Calif. / Mar 09, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year ended December 31, 2022 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results. “2022 marked a... Read More

CARLSBAD, Calif. / Mar 06, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes in addition to visual data from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Association for Research in... Read More

CARLSBAD, Calif. / Mar 02, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage management will also... Read More

CARLSBAD, Calif. / Feb 22, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LC T X ), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc. (“Eterna”) for the development of novel... Read More

CARLSBAD, Calif. / Feb 08, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on its auditory neuronal cell therapy program (ANP1), for the treatment of hearing loss, with an initial focus on auditory neuropathy spectrum disorders. Preclinical testing of ANP1 has... Read More